Analysts’ Weekly Ratings Changes for BioNTech (BNTX)

A number of firms have modified their ratings and price targets on shares of BioNTech (NASDAQ: BNTX) recently:

• 12/11/2024 – BioNTech is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $170.00 price target on the stock.
• 12/2/2024 – BioNTech had its “outperform” rating reaffirmed by analysts at BMO Capital Markets.
• 11/27/2024 – BioNTech had its price target raised by analysts at Canaccord Genuity Group Inc. from $171.00 to $171.44. They now have a “buy” rating on the stock.
• 11/26/2024 – BioNTech had its price target lowered by analysts at JPMorgan Chase & Co. from $124.00 to $122.00. They now have a “neutral” rating on the stock.
• 11/19/2024 – BioNTech was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating. They now have a $125.00 price target on the stock, up previously from $110.00.
• 11/19/2024 – BioNTech is now covered by analysts at Berenberg Bank. They set a “buy” rating and a $130.00 price target on the stock.
• 11/18/2024 – BioNTech had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.
• 11/14/2024 – BioNTech had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $171.00 price target on the stock.
• 11/8/2024 – BioNTech was upgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “buy” rating. They now have a $137.00 price target on the stock, up previously from $90.00.
• 11/5/2024 – BioNTech had its price target lowered by analysts at TD Cowen from $132.00 to $122.00. They now have a “hold” rating on the stock.
• 11/4/2024 – BioNTech had its price target lowered by analysts at JPMorgan Chase & Co. from $125.00 to $124.00. They now have a “neutral” rating on the stock.
• 10/21/2024 – BioNTech had its price target raised by analysts at TD Cowen from $85.00 to $132.00. They now have a “hold” rating on the stock.

BioNTech Stock Down 5.1 %

BNTX opened at $114.22 on Tuesday. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The firm’s 50 day simple moving average is $113.72 and its two-hundred day simple moving average is $100.54. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $27.15 billion, a PE ratio of -54.39 and a beta of 0.22.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm’s revenue was up 38.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.73 EPS. As a group, equities analysts forecast that BioNTech SE will post -3.72 EPS for the current year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC raised its stake in BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after purchasing an additional 111 shares during the period. Blue Trust Inc. boosted its position in shares of BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares during the last quarter. Gallacher Capital Management LLC grew its stake in BioNTech by 12.1% during the second quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company’s stock valued at $294,000 after acquiring an additional 395 shares in the last quarter. TD Asset Management Inc increased its holdings in BioNTech by 6.1% in the 2nd quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after acquiring an additional 435 shares during the last quarter. Finally, Planning Capital Management Corp lifted its stake in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after purchasing an additional 450 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.